Geode Capital Management
SXTP icon

Geode Capital Management’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Geode Capital Management’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6K Sell
14,551
-1,744
-11% -$2.81K ﹤0.01% 4352
2026
Q1 		$28.5K Buy
16,295
+13,183
+424% +$37.4K ﹤0.01% 4417
2025
Q4 		$6.33K Hold
3,112
– – ﹤0.01% 4450
2025
Q3 		$18.3K Sell
3,112
-17
-0.5% -$104 ﹤0.01% 4422
2025
Q2 		$29.7K Buy
3,129
+148
+5% +$1.48K ﹤0.01% 4312
2025
Q1 		$21.5K Buy
+2,981
New +$36.7K ﹤0.01% 4334
2024
Q3 		– Sell
-158
Closed -$9.61K – 4580
2024
Q2 		$9.61K Buy
+158
New +$10K ﹤0.01% 4548

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's SXTP Position: Q2 2026 in Review

Geode Capital Management reduced its 60 Degrees Pharmaceuticals (SXTP) stake by 11% in Q2 2026, selling an estimated $2.81K and leaving 14,551 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4352.

Geode Capital Management first reported a position in SXTP in Q2 2024 and has held it in 7 quarters since. The position peaked at $29.7K in Q2 2025. 4 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

  • Geode Capital Management held 14,551 shares of 60 Degrees Pharmaceuticals worth $25.6K as of Q2 2026.
  • Geode Capital Management sold 1,744 60 Degrees Pharmaceuticals shares in Q2 2026, an estimated $2.81K.
  • 60 Degrees Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4352 holding.
  • Geode Capital Management first reported a position in 60 Degrees Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Geode Capital Management's 60 Degrees Pharmaceuticals position peaked at $29.7K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.